New study aims to improve cervical cancer monitoring for HIV-Positive women
NCT ID NCT07202936
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This observational study follows 168 women living with HIV in Zimbabwe who have been treated for cervical pre-cancer. Researchers want to learn how often the disease comes back and whether HPV or DNA tests can predict recurrence. Participants will be monitored every six months for two years with biopsies and cervical samples.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to better guidelines for monitoring cervical pre-cancer in women with HIV, reducing recurrence and cancer risk.
- What could go wrong
- This is an observational study, not a treatment trial, so it won't directly test a new therapy. Results may not apply to other countries or populations.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL INTRAEPITHELIAL NEOPLASIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Women's Health Centre at Newlands Clinic
Harare, Zimbabwe
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- One drop, many cancers? a rapid test aims to spot cancer signals in blood, urine, or saliva
- Can a portable heat device match cryotherapy for cervical precancer?
- Long-acting HIV shot studied in patients with severe kidney problems
- Particle beam and immune therapy join forces against cervical cancer
- Can a daily supplement help the body fight off HPV?
- Could a Light-Activated cream replace surgery for cervical precancer?